Literature DB >> 9818745

Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B.

A G Vonk1, M G Netea, N E Denecker, I C Verschueren, J W van der Meer, B J Kullberg.   

Abstract

Amphotericin B is an antifungal drug associated with side effects such as fever and chills, symptoms which may be mediated by pro-inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumour necrosis factor-alpha (TNFalpha). We assessed the capacity of amphotericin B to modulate production of these pro-inflammatory cytokines as well as the anti-inflammatory IL-1 receptor antagonist (IL-1ra), induced by LPS, heat-killed Candida albicans or Staphylococcus aureus. The results of the present study show that amphotericin B slightly increased the production of pro-inflammatory cytokines by human mononuclear cells (PBMC), whereas the production of the anti-inflammatory cytokine IL-1ra was significantly inhibited. This results in a shift towards pro-inflammatory cytokine production, as indicated by a decreased IL-1ra/IL-1beta ratio. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) indicated that levels of IL-1beta and TNFalpha mRNA were increased. In conclusion, amphotericin B is able to cause a shift towards pro-inflammatory cytokine production by human PBMC. This may explain the side effects, such as fever and chills, observed after treatment of patients with amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818745     DOI: 10.1093/jac/42.4.469

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.

Authors:  M Simitsopoulou; E Roilides; J Dotis; M Dalakiouridou; F Dudkova; E Andreadou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation.

Authors:  S Rama Iñiguez; M A Dea-Ayuela; J A Sanchez-Brunete; J J Torrado; J M Alunda; F Bolas-Fernández
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units.

Authors:  D G Wolf; R Falk; M Hacham; B Theelen; T Boekhout; G Scorzetti; M Shapiro; C Block; I F Salkin; I Polacheck
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

4.  Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Authors:  Karl V Clemons; Julie A Schwartz; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

5.  Characterization of and host response to tyramine substituted-hyaluronan enriched fascia extracellular matrix.

Authors:  Likang Chin; Anthony Calabro; E Rene Rodriguez; Carmela D Tan; Esteban Walker; Kathleen A Derwin
Journal:  J Mater Sci Mater Med       Date:  2011-05-07       Impact factor: 3.896

6.  Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans.

Authors:  A L Baltch; R P Smith; M A Franke; W J Ritz; P B Michelsen; L H Bopp
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 8.  Leishmania RNA virus: when the host pays the toll.

Authors:  Mary-Anne Hartley; Catherine Ronet; Haroun Zangger; Stephen M Beverley; Nicolas Fasel
Journal:  Front Cell Infect Microbiol       Date:  2012-07-12       Impact factor: 5.293

9.  Enhancement of a TH1 immune response in amphotericin B-treated mucocutaneous leishmaniasis.

Authors:  Washington R Cuna; Rianed Velasquez; Janeth Riva; Ingrid Guachalla; Celeste Rodríguez
Journal:  J Biomed Biotechnol       Date:  2007
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.